
Eli Lilly says once‑daily oral weight‑loss pill could reach UK as soon as 2026
Orforglipron cut weight by an average 12.4% in a 3,127‑participant trial; company plans regulatory submissions by year‑end

Orforglipron cut weight by an average 12.4% in a 3,127‑participant trial; company plans regulatory submissions by year‑end

Orforglipron, an oral GLP‑1 therapy, reduced weight by an average of 12.4% in a 72‑week trial; company plans regulatory submissions and cites similar side‑effect profile to injectable treatments

Company plans regulatory submissions after late-stage trial results; pill aims to offer a room-temperature, once-daily alternative to injectable obesity drugs

Orforglipron, an oral drug that targets GLP‑1 receptors, produced an average 12.4% weight reduction in a 3,127‑participant study; company plans regulatory filings by year‑end

Company plans regulatory filings after phase‑3 results showing average 12.4% weight loss; pill aimed at patients who prefer not to use injectable therapies

Dr. Demetre Daskalakis, who recently resigned from the CDC’s immunization center, called the Kentucky senator a 'bigoted bully' after comments tying his personal life to his fitness for public service.

Orforglipron, a once‑daily GLP‑1 tablet, showed significant weight reduction in a large trial and is being prepared for regulatory submission; side effects were similar to injectable therapies.

Columnist recommends physician evaluation, psychotherapy, medication and condition-specific communities to combat isolation and regain activity

Experts advise exercise, dietary changes, toxin avoidance, genetic counseling, tailored screening and, in some cases, preventive surgery to reduce inherited cancer risk